BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32901094)

  • 1. The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer.
    Naha U; Freedland SJ; Abern MR; Moreira DM
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):335-340. PubMed ID: 32901094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
    Moreira DM; Fleshner NE; Freedland SJ
    J Urol; 2015 Nov; 194(5):1258-63. PubMed ID: 25988518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort.
    Marzouk K; Assel M; Ehdaie B; Vickers A
    J Urol; 2018 Dec; 200(6):1250-1255. PubMed ID: 29886089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance.
    Alvisi MF; Repetto C; Rancati T; Badenchini F; Magnani T; Marenghi C; Villa S; Nicolai N; Salvioni R; Avuzzi B; Valdagni R; Bellardita L;
    Tumori; 2018 Jun; 104(3):172-178. PubMed ID: 28623635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
    Venderbos LD; van den Bergh RC; Roobol MJ; Schröder FH; Essink-Bot ML; Bangma CH; Steyerberg EW; Korfage IJ
    Psychooncology; 2015 Mar; 24(3):348-54. PubMed ID: 25138075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer.
    Tavlarides AM; Ames SC; Diehl NN; Joseph RW; Castle EP; Thiel DD; Broderick GA; Parker AS
    Psychooncology; 2013 Jun; 22(6):1328-35. PubMed ID: 22855322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer.
    Tavlarides AM; Ames SC; Thiel DD; Diehl NN; Parker AS
    Psychooncology; 2015 Apr; 24(4):451-7. PubMed ID: 24953309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the psychological impact of active surveillance or active treatment in newly diagnosed favorable-risk prostate cancer patients: A 9-month longitudinal study.
    Ruane-McAteer E; Porter S; O'Sullivan J; Dempster M; Prue G
    Psychooncology; 2019 Aug; 28(8):1743-1752. PubMed ID: 31243872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with Discontinuation of Active Surveillance among Men with Low-Risk Prostate Cancer: A Population-Based Study.
    Timilshina N; Komisarenko M; Martin LJ; Cheung DC; Alibhai S; Richard PO; Finelli A
    J Urol; 2021 Oct; 206(4):903-913. PubMed ID: 34412510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-cultural differences in men on active surveillance' anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study.
    Dordoni P; Remmers S; Valdagni R; Bellardita L; De Luca L; Badenchini F; Marenghi C; Roobol MJ; Venderbos LDF
    BMC Urol; 2022 Jul; 22(1):110. PubMed ID: 35850672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer.
    Tan HJ; Marks LS; Hoyt MA; Kwan L; Filson CP; Macairan M; Lieu P; Litwin MS; Stanton AL
    J Urol; 2016 Jun; 195(6):1724-30. PubMed ID: 26872841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
    BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.